Table 3.
Clinical trials investigating the combination of small molecule inhibitors with immune checkpoint blockade.
| Clinical Trial | Trial Title | Conditions | Treatment | Phases |
|---|---|---|---|---|
| NCT04265872 | Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC | Breast cancer | Bortezomib Pembrolizumab Cisplatin |
Phase 1 |
| NCT04258683 | A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE | Multiple myeloma | Cyclophosphamide Bortezomib Dexamethasone Pembrolizumab |
Phase 2 |
|
NCT04191096 NCT04934722 |
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) | Metastatic hormone-sensitive prostate cancer | Enzalutamide Pembrolizumab |
Phase 3 |
| NCT04471974 | ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer |
Castration-resistant prostate carcinoma Metastatic prostate adeno- carcinoma Metastatic prostate small cell carcinoma Stage IV/IVA/IVB prostate cancer AJCC v8 |
ZEN-3694 Enzalutamide Pembrolizumab |
Phase 2 |
| NCT04946370 | Maximizing Responses to Anti-PD1 Immunotherapy With PSMA-targeted Alpha Therapy in mCRPC | Prostate cancer | 225Ac-J591 Pembrolizumab Androgen receptor pathway inhibitor |
Phase 1 Phase 2 |
| NCT04262154 | Study of Abiraterone Acetate, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone- sensitive Prostate Cancer |
Metastatic prostate cancer | Atezolizumab Abiraterone acetate Prednisone Lupron® (leuprolide) SBRT Enzalutamide |
Phase 2 |
| NCT04190056 | Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer |
Breast cancer | Pembrolizumab Tamoxifen Vorinostat |
Phase 2 |
225Ac-J591: alpha-emitter actinium-225 conjugated to the anti-PSMA antibody J591; NDMM: newly diagnosed multiple myeloma; NTE: not transplant eligible; SBRT: stereotactic body radiotherapy; ZEN-3694: BET bromodomain inhibitor.